aap Implantate AG / aap is granted two European patents for innovative magnesium technology, making great progress in development of resorbable implants . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE), a developer, manufacturer and distributor of innovative trauma products, announced that the European Patent Office will shortly grant it two key patents for developing resorbable magnesium implants. The first patent (WO2010/017959) will protect an efficient way to manufacture magnesium implants while the second (WO2012/007181) relates to a coating technology for magnesium implants. Final granting of the two patents now depends solely on the fulfilment of formal conditions such as payment of a patent fee. The two European patents will then be nationalised in many key markets in Europe and published in different languages.
In the magnesium technology area aap Implantate AG aims to develop implants that after successful fracture or defect healing are biodegradable in the body, thereby making a second operation to remove the material superfluous. The implant must have high mechanical properties and also be resorbable. In this connection the first patent (WO2010/017959) protects the manufacture of magnesium implants with different porosity. aap Implantate AG has succeeded in manufacturing screws with a very porous core and a highly compacted outer skin. This makes the implant very stable for an initial period during which healing is under way, after which it can degrade relatively fast. The second patent (WO2012/007181) relates to a coating technology for magnesium implants that can influence the beginning of resorption. The essential biomechanical stability of the implant can thus be maintained during healing for as long as is required until healing of the bone is completed.
"The latest research findings and publications have shown especially that the processing and coating of the magnesium are the key to success with resorbable magnesium implants", says Bruke Seyoum Alemu, CEO of aap Implantate AG. "As a result these two patents have enabled us to take a further and significant step forward in expanding our strategic patent-protected portfolio."

aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire
HUG#1888502

--- End of Message ---

aap Implantate AG
Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


Share
© GlobeNewswire - 2015